The products of various NF-κB target genes, most notably cyclin D1, BCL-2, Bcl-XL, survivin and XIAP, have been implicated, each in diverse oncological contexts, as mediators of NF-κB-dependent tumour-cell survival leading to radiotherapy and/or chemotherapy resistance [79,80]. This evidence concerns the gene NFKB1 and neoplasm.